Pfizer (PFE) Raw Materials (2009 - 2019)

Pfizer (PFE) has 11 years of Raw Materials data on file, last reported at $560.0 million in Q1 2019.

• Raw Materials for Q1 2019 came in at $560.0 million, down 32.12% year-over-year; the trailing twelve-month figure through Mar 2019 was $560.0 million (down 32.12% YoY), and the FY2018 annual result was $546.0 million, down 30.71% from the prior year.
• Raw Materials improved to $560.0 million in Q1 2019 per PFE's latest filing, from $546.0 million in the prior quarter.
• Over five years, Raw Materials peaked at $950.0 million in Q3 2016 and troughed at $475.0 million in Q1 2015.
• A 5-year average of $754.1 million and a median of $809.0 million in 2016 frame the typical range for Raw Materials.
• The sharpest annual moves came in 2016 and 2019: Raw Materials surged 84.82% in 2016, then plunged 32.12% in 2019.
• A 5-year view of Raw Materials shows it stood at $867.0 million in 2015, then decreased by 8.54% to $793.0 million in 2016, then declined by 0.63% to $788.0 million in 2017, then tumbled by 30.71% to $546.0 million in 2018, then advanced by 2.56% to $560.0 million in 2019.
• Business Quant data shows PFE's Raw Materials at $560.0 million in Q1 2019, $546.0 million in Q4 2018, and $839.0 million in Q3 2018.